{"brief_title": "Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.", "brief_summary": "The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.", "condition": ["Lymphoma, Non-Hodgkin"], "intervention_type": ["Drug"], "intervention_name": ["Recombinant Human Interleukin-2 and Rituximab"], "criteria": "Inclusion: - Diagnosis: CD20+ B-cell non-Hodgkin's lymphoma (NHL) classified as intermediate- or high-grade according to the Working Formulation, subtypes D to H. Must have measureable progressive or refractory disease after no more than three prior chemotherapy regimens. Exclusion: - Clinically significant cardiac dysfunction, or a history of myocardial infarction or heart failure within 6 months of first study treatment - Clinically significant pulmonary dysfunction. - Liver disease (note hepatitis C seropositive subjects may be enrolled if they have no active disease as demonstrated by undetectable HCV viral loads, biopsy showing no active disease, and/or history of normal transaminases on at least three different dates within one year of first study treatment). - Symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism. - History of autoimmune disease. - History of positive serology for human immunodeficiency virus (HIV).", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Intermediate and High-Grade Non-Hodgkin's Lymphoma", "mesh_term": ["Lymphoma", "Lymphoma, Non-Hodgkin", "Aldesleukin", "Rituximab", "Interleukin-2"], "id": "NCT00045864"}